Announcement of Shandong Buchang Pharmaceutical Co., Ltd. on the cancellation of its wholly-owned subsidiary
Securities code: 603858 Securities abbreviation: Buchang Pharmaceutical Announcement number: 2026-035
Shandong Buchang Pharmaceutical Co., Ltd.
Announcement on Cancellation of Wholly-Owned Subsidiaries
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Shaanxi Buchang Pharmaceutical Research Institute Co., Ltd. (hereinafter referred to as "Shaanxi Buchang Pharmaceutical") is a wholly-owned subsidiary of Shandong Buchang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"). Based on the current actual operating conditions and subsequent business development plans, the company decided to cancel Shaanxi Buchang Pharmaceutical in order to optimize resource allocation and organizational structure, reduce management costs, and improve operational management efficiency.
This cancellation does not involve related transactions, nor does it constitute a major asset reorganization stipulated in the "Administrative Measures for Major Asset Reorganization of Listed Companies", and does not need to be submitted to the board of directors or shareholders' meeting for approval.
The above matters have been completed, and the company recently received the "Registration Notice" issued by the High-tech Zone Branch of Xi'an Municipal Administration for Market Regulation.
1. Basic situation of Shaanxi Buchang Pharmaceutical
Name: Shaanxi Buchang Pharmaceutical Research Institute Co., Ltd.
Type: Limited liability company (foreign-invested enterprise legal person sole proprietorship)
Legal representative: Wang Yimin
Registered capital: RMB 800,000
Date of establishment: October 18, 2019
Address: No. 70, West Avenue, New Industrial Park, Zhangba Street Office, High-tech Zone, Xi'an City, Shaanxi Province
Business scope: technological development of pharmaceuticals; medical research and experimental development (excluding treatment technology development and application). (Projects that require approval according to law can only be carried out with the approval of relevant departments) (The above business scope shall not involve projects within the scope of special management measures for foreign investment access)
Equity structure: The company holds 100% of its shares.
Main financial data: As of now, Shaanxi Buchang Pharmaceutical has not carried out actual operating activities and has no financial data.
2. Reasons for canceling wholly-owned subsidiaries and their impact on the company
In order to further optimize resource allocation, reduce management costs, and improve operational management efficiency, the company decided to cancel its wholly-owned subsidiary Shaanxi Buchang Pharmaceutical. After this cancellation, there will be no substantial impact on the company's consolidated statements, no adverse impact on the company's overall business development and profitability, and no harm to the interests of the company and shareholders.
Announcement is hereby made.
Board of Directors of Shandong Buchang Pharmaceutical Co., Ltd.
April 8, 2026